Clinical Trial Update: Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial of AXL1717 in recurrent malignant astrocytomas (glioblastoma, gliosarcoma) with terminated status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Ependymoma
• Anaplastic Oligoastrocytoma
• Anaplastic Oligodendroglioma
• Glioblastoma
• Gliosarcoma

Drugs mentioned

• AXL1717 (AXL1717)

Snippet

Sponsor: Rush University Medical Center | Conditions: Glioblastoma, Gliosarcoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-05-22